Piper Jaffray Downgrades Illumina Stock | GenomeWeb

NEW YORK (GenomeWeb News) – Investment bank Piper Jaffray has downgraded Illumina to Neutral from Overweight and also has cut its price target on the stock.

Senior Research Analyst William Quirk said in a note published today that the "downgrade reflects concerns over increasingly more challenging 2H13 comps, likely limiting upside in the back half of the year, and with the current valuation."

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.